Printed from https://ideas.repec.org/s/spr/pharme8.html
Content
January 2013, Volume 31, Issue 1
- 77-85 Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials
by Joanna Thorn & Sian Noble & William Hollingworth - 87-89 A Comment on Boyers et al.: “Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal”
by Rachel Allen & Andres Brainsky & Kelly Grotzinger & Tito Roccia - 91-91 The Authors’ Reply to Allen et al.: “A Comment on Boyers et al.: ‘Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal’”
by Dwayne Boyers & Xueli Jia & David Jenkinson & Graham Mowatt
December 2012, Volume 30, Issue 12
- 1101-1117 Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
by Marta O. Soares & Luísa Canto e Castro - 1101-1117 Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
by Marta Soares & Luísa Canto e Castro - 1119-1132 Bevacizumab for Metastatic Colorectal Cancer
by Sophie Whyte & Abdullah Pandor & Matt Stevenson - 1119-1132 Bevacizumab for Metastatic Colorectal Cancer
by Sophie Whyte & Abdullah Pandor & Matt Stevenson - 1133-1143 A Systematic Review and Critical Assessment of Health State Utilities
by Scott Doyle & Andrew Lloyd & Lee Moore & Joshua Ray & Alastair Gray - 1133-1143 A Systematic Review and Critical Assessment of Health State Utilities
by Scott Doyle & Andrew Lloyd & Lee Moore & Joshua Ray & Alastair Gray - 1145-1156 Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis
by Cécile Gaujoux-Viala & Bruno Fautrel - 1145-1156 Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis
by Cécile Gaujoux-Viala & Bruno Fautrel - 1157-1171 Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis
by Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain A. Lang & Ken Stein - 1157-1171 Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis
by Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain Lang & Ken Stein - 1173-1186 Chemotherapy Administration
by Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward - 1173-1186 Chemotherapy Administration
by Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward - 1187-1202 What’s Good and Bad About Contraceptive Products?
by Stephanie A. Knox & Rosalie C. Viney & Deborah J. Street & Marion R. Haas & Denzil G. Fiebig & Edith Weisberg & Deborah Bateson - 1187-1202 What’s Good and Bad About Contraceptive Products?
by Stephanie Knox & Rosalie Viney & Deborah Street & Marion Haas & Denzil Fiebig & Edith Weisberg & Deborah Bateson - 1203-1214 Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
by Liv Ariane Augestad & Kim Rand-Hendriksen & Ivar Sønbø Kristiansen & Knut Stavem - 1203-1214 Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
by Liv Augestad & Kim Rand-Hendriksen & Ivar Kristiansen & Knut Stavem
November 2012, Volume 30, Issue 11
- 981-989 Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis
by Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn - 991-1004 Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years
by Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott - 1005-1013 The Burden of Moderate to Severe Psoriasis
by Giovanna Raho & Daniela Mihajlova Koleva & Livio Garattini & Luigi Naldi - 1015-1034 Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups
by Ava John-Baptiste & Man Yeung & Victoria Leung & Gabrielle Velde & Murray Krahn - 1035-1049 Losing Sight of the Wood for the Trees
by Paul Dolan & Henry Lee & Tessa Peasgood - 1051-1065 A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
by Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith - 1067-1084 The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
by Laura Panattoni & Paul Brown & Braden Ao & Mark Webster & Patrick Gladding - 1085-1095 The General Public’s Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer’s Disease Medication
by Mark Oremus & Jean-Eric Tarride & Parminder Raina & Lehana Thabane & Gary Foster & Charlie Goldsmith & Natasha Clayton
October 2012, Volume 30, Issue 10
- 859-868 Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials
by Anirban Basu & David Meltzer - 869-885 New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses
by Douglas Mapel & Melissa Roberts - 887-902 Counting the Cost of Not Costing HIV Health Facilities Accurately
by Eduard Beck & Carlos Avila & Sofia Gerbase & Guy Harling & Paul Lay - 903-923 The Cost Effectiveness of Newer Epilepsy Treatments
by Kristian Bolin & Lars Forsgren - 925-940 The State of Health Economic Research in South Africa
by Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza - 941-959 Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting
by Laura McCullagh & Cathal Walsh & Michael Barry - 961-976 Patient Preferences for Community Pharmacy Asthma Services
by Pradnya Naik-Panvelkar & Carol Armour & John Rose & Bandana Saini - 977-977 Validity of Cost and Utility Results?
by Alex Diamantopoulos & Laura Sawyer & Sarika Ogale & Fred Dejonckheere - 977-978 The Authors’ Reply
by Mark Bounthavong & Christine Nguyen & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale - 979-979 Is There a Role for Pharmacoeconomics in Decision Making?
by Johan Luijn - 980-980 The Authors’ Reply
by Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel
September 2012, Volume 30, Issue 9
- 749-762 Assessing the Quality of Pharmacoeconomic Studies in India
by Pooja Desai & Hitesh Chandwani & Karen Rascati - 763-777 Cost of Illness of Cystic Fibrosis in Germany
by Mareike Heimeshoff & Helge Hollmeyer & Jonas Schreyögg & Oliver Tiemann & Doris Staab - 779-794 Reimbursement Decisions of the All Wales Medicines Strategy Group
by Warren Linley & Dyfrig Hughes - 795-807 Lost Productivity in Four European Countries among Patients with Rheumatic Disorders
by Saskia Knies & Math Candel & Annelies Boonen & Silvia Evers & Andre Ament & Johan Severens - 809-823 Costs Associated with Febrile Neutropenia in the US
by Shannon Michels & Rich Barron & Matthew Reynolds & Karen Tomic & Jingbo Yu & Gary Lyman - 825-840 A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease
by Petra Menn & Reiner Leidl & Rolf Holle - 841-855 Dabigatran Etexilate
by Kate McKeage - 857-858 Caregivers’ Quality of Life and Economic Evaluations
by Afschin Gandjour - 858-858 The Authors’ Reply
by Hareth Al-Janabi & Terry Flynn & Joanna Coast
August 2012, Volume 30, Issue 8
- 1-15 Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
by Vanja Sikirica & M. Erder & Jipan Xie & Dendy Macaulay & Melissa Diener & Paul Hodgkins & Eric Wu - 633-635 Valuing Children’s Health
by Eve Wittenberg - 637-645 Comparative Effectiveness and Child Health
by Lisa Prosser - 647-660 Economic Evaluations of Childhood Influenza Vaccination
by Anthony Newall & Mark Jit & Philippe Beutels - 661-679 Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders
by J. Tilford & Nalin Payakachat & Erica Kovacs & Jeffrey Pyne & Werner Brouwer & Todd Nick & Jayne Bellando & Karen Kuhlthau - 681-695 The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt
by Mark Connolly & Oleksandr Topachevskyi & Baudouin Standaert & Omayra Ortega & Maarten Postma - 697-712 A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma
by Wendy Ungar & Katherine Boydell & Sharon Dell & Brian Feldman & Deborah Marshall & Andrew Willan & James Wright - 713-727 Developing Adolescent-Specific Health State Values for Economic Evaluation
by Julie Ratcliffe & Terry Flynn & Frances Terlich & Katherine Stevens & John Brazier & Michael Sawyer - 729-747 Valuation of the Child Health Utility 9D Index
by Katherine Stevens
July 2012, Volume 30, Issue 7
- 537-549 Cost Effectiveness of Rituximab for Non-Hodgkin’s Lymphoma
by Philipp Auweiler & Dirk Müller & Stephanie Stock & Andreas Gerber - 551-564 Economic Evaluation of Smoking-Cessation Therapies
by Kristian Bolin - 565-573 Hospital Reimbursement Price Cap for Cancer Drugs
by Albane Degrassat-Théas & M. Bensadon & C. Rieu & M. Angalakuditi & C. Pen & P. Paubel - 575-593 Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
by Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale - 595-609 Duloxetine Use in Chronic Low Back Pain
by Jasmina Ivanova & Howard Birnbaum & Evan Kantor & Matt Schiller & Ralph Swindle - 611-631 Quetiapine
by Greg Plosker
June 2012, Volume 30, Issue 6
- 447-459 Value of Information and Pricing New Healthcare Interventions
by Andrew Willan & Simon Eckermann - 461-482 A Critical Review of Model-Based Economic Studies of Depression
by Hossein Ali Afzali & Jonathan Karnon & Jodi Gray - 483-495 Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
by Dwayne Boyers & Xueli Jia & David Jenkinson & Graham Mowatt - 497-511 Pharmacoeconomics of the Myeloid Growth Factors
by Bradford Hirsch & Gary Lyman - 513-530 Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
by Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton - 531-532 The Lack of Impact of Quality-of-Life Measures in Schizophrenia: A Shared Responsibility?
by Laurent Boyer & Pascal Auquier - 532-533 The Authors’ Reply
by A. Awad & Lakshmi Voruganti - 534-535 Erratum to Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study
by Laura Pizzi & Amy Talati & Eric Gemmen & Naomi Dahl & Thomas Bunz & Peter Sand
April 2012, Volume 30, Issue 4
- 257-270 Golimumab for the Treatment of Psoriatic Arthritis
by Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott - 271-302 Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease
by Maureen Rutten-van Mölken & Lucas Goossens - 303-321 Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes
by Jaime Latour-Pérez & Eva -Miguel-Balsa - 323-336 Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
by Howard Birnbaum & Crystal Pike & Ritesh Banerjee & Tracy Waldman & Mary Cifaldi - 337-353 Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program
by Nadia Demarteau & Thomas Breuer & Baudouin Standaert
March 2012, Volume 30, Issue 3
- 171-181 Population–versus Cohort–Based Modelling Approaches
by Olivier Ethgen & Baudouin Standaert - 183-195 Measuring Quality of Life in Patients with Schizophrenia
by A. Awad & Lakshmi Voruganti - 197-211 Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7
by Frank Lichtenberg - 213-217 Pricing Human Papillomavirus Vaccines
by Livio Garattini & Katelijne Vooren & Alessandro Curto - 219-227 Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands
by Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel - 229-246 Common Drug Review Recommendations
by Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree - 247-256 Rufinamide
by Paul McCormack
February 2012, Volume 30, Issue 2
- 83-86 Health Utility Elicitation
by Lisa Prosser & Scott Grosse & Eve Wittenberg - 87-101 Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective
by Aurea Duran & Nishan Sengupta & Alexander Diamantopoulos & Fiona Forster & Louis Kwong & Michael Lees - 103-118 Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer
by Robert Griffiths & Richard Barron & Michelle Gleeson & Mark Danese & Anthony O’Hagan & Victoria Chia & Jason Legg & Gary Lyman - 119-126 Incorporating Calibrated Model Parameters into Sensitivity Analyses
by Douglas Taylor & Vivek Pawar & Denise Kruzikas & Kristen Gilmore & Myrlene Sanon & Milton Weinstein - 127-131 Why Not Real Economics?
by F. Reed Johnson - 133-136 Real Economics Needs to Reflect Real Decisions
by Mark Sculpher & Karl Claxton - 137-146 Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery
by Michael Holmes & Christopher Carroll & Diana Papaioannou - 147-170 Osteoporotic Fractures
by Sangeeta Budhia & Yeshi Mikyas & Michael Tang & Enkhe Badamgarav
January 2012, Volume 30, Issue 1
- 1-16 Economic and Humanistic Burden of External Genital Warts
by Adam Raymakers & Mohsen Sadatsafavi & Fawziah Marra & Carlo Marra - 17-34 Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer
by Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot - 35-46 Dronedarone for the Treatment of Atrial Fibrillation
by Claire McKenna & Emma Maund & Muhammad Sarowar & David Fox & Matt Stevenson & Chris Pepper & Nerys Woolacott & Stephen Palmer - 47-61 Does the EQ-5D Reflect Lost Earnings?
by Carl Tilling & Marieke Kro & Aki Tsuchiya & John Brazier & Job Exel & Werner Brouwer - 63-80 A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis
by Christopher Fitzpatrick & Katherine Floyd - 81-81 Erratum to Systematic Reviewof the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis
by C. Fitzpatrick & K. Floyd
December 2011, Volume 29, Issue 12
- 1014-1014 Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK
by Á Benedict & L Verdian & G Maclaine - 1015-1023 QALYs and Carers
by Hareth Al-Janabi & Terry Flynn & Joanna Coast - 1025-1049 Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease
by Judith Dams & Bernhard Bornschein & Jens Reese & Annette Conrads-Frank & Wolfgang Oertel & Uwe Siebert & Richard Dodel - 1063-1073 Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection
by Hui-Fang Hung & Hsiu-Hsi Chen - 1075-1091 Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
by Helen Dakin & Morris Sherman & Scott Fung & Carrie Fidler & Anthony Bentley
November 2011, Volume 29, Issue 11
- 933-949 Sample Size Determination for Cost-Effectiveness Trials
by Andrew Willan - 963-975 Willingness to Pay for Adverse Drug Event Regulatory Actions
by Jacoline Bouvy & Just Weemers & Huub Schellekens & Marc Koopmanschap - 977-988 Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma
by Ateesha Mohamed & A. Hauber & Maureen Neary - 989-1009 Rotavirus Vaccine RIX4414 (Rotarix™)
by Greg Plosker
October 2011, Volume 29, Issue 10
- 839-861 A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease
by Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne - 875-882 Does the Market Share of Generic Medicines Influence the Price Level?
by Pieter Dylst & Steven Simoens
September 2011, Volume 29, Issue 9
- 781-806 Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand
by Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien
August 2011, Volume 29, Issue 8
- 653-671 Cost-of-Illness Studies
by Allison Larg & John Moss - 693-704 Cost Estimation of Cardiovascular Disease Events in the US
by Amy O’Sullivan & Jaime Rubin & Joshua Nyambose & Andreas Kuznik & David Cohen & David Thompson
July 2011, Volume 29, Issue 7
- 555-561 Prioritizing Comparative Effectiveness Research
by Afschin Gandjour - 563-577 Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies
by Simon Eckermann & Andrew Willan - 579-599 Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV
by Omar Galárraga & Veronika Wirtz & Alejandro Figueroa-Lara & Yared Santa-Ana-Tellez & Ibrahima Coulibaly & Kirsi Viisainen & Antonieta Medina-Lara & Eline Korenromp - 601-619 Do Productivity Costs Matter?
by Marieke Krol & Jocé Papenburg & Marc Koopmanschap & Werner Brouwer - 621-635 Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder
by Arnie Aldridge & Larry Kroutil & Alexander Cowell & Daniel Reeves & David Brunt
May 2011, Volume 29, Issue 5
- 414-414 Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease
by Nicole Mittmann & Paul Hernandez & Carl Mellström & Lance Brannman & Tobias Welte
April 2011, Volume 29, Issue 4
- 287-296 Sample Size and Power for Cost-Effectiveness Analysis (Part 2)
by Henry Glick
March 2011, Volume 29, Issue 3
- 189-198 Sample Size and Power for Cost-Effectiveness Analysis (Part 1)
by Henry Glick - 199-211 Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children
by Chantal Boonacker & Pieter Broos & Elisabeth Sanders & Anne Schilder & Maroeska Rovers - 239-250 Comparing Methods of Data Synthesis
by Mark Oppe & Maiwenn Al & Maureen Rutten-Mölken
February 2011, Volume 29, Issue 2
- 107-131 Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
by Paul Mitchell & Lieven Annemans & Richard White & Meghan Gallagher & Simu Thomas
January 2011, Volume 29, Issue 1
- 1-15 Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
by Martin Hoyle - 17-33 Effects of Reference Pricing in Pharmaceutical Markets
by Matteo Galizzi & Simone Ghislandi & Marisa Miraldo - 35-49 Calibrating Models in Economic Evaluation
by Tazio Vanni & Jonathan Karnon & Jason Madan & Richard White & W. Edmunds & Anna Foss & Rosa Legood - 51-62 Calibrating Models in Economic Evaluation
by Jonathan Karnon & Tazio Vanni - 63-82 Availability of and Access to Orphan Drugs
by Carl Blankart & Tom Stargardt & Jonas Schreyögg - 83-84 Is There a Role for Pharmacoeconomics in Developing Countries?
by Asrul Shafie & Mohamed Hassali - 84-86 The Authors’ Reply
by Zaheer-Ud-Din Babar & Shane Scahill
December 2010, Volume 28, Issue 12
- 1109-1121 A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
by Ifigeneia Mavranezouli
November 2010, Volume 28, Issue 11
- 987-993 An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions
by Phill O’Neill & Nancy Devlin - 995-1000 Methods of Model Calibration
by Douglas Taylor & Vivek Pawar & Denise Kruzikas & Kristen Gilmore & Ankur Pandya & Rowan Iskandar & Milton Weinstein - 1001-1013 Cost Effectiveness of Pharmacogenomics
by William Wong & Josh Carlson & Rahber Thariani & David Veenstra - 1025-1039 Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
by Teresa Kauf & Raymond Farkouh & Stephanie Earnshaw & Maria Watson & Penny Maroudas & Mike Chambers - 1041-1054 Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy
by Mario Eandi & Lorenzo Pradelli & Sergio Iannazzo & Silvia Chiroli & Giuseppe Pontoriero - 1055-1064 Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses A Decision Tree Model
by Edward Wilson
October 2010, Volume 28, Issue 10
- 813-830 International Comparison of Comparative Effectiveness Research in Five Jurisdictions
by Adrian Levy & Craig Mitton & Karissa Johnston & Brian Harrigan & Andrew Briggs - 877-887 Comparative Effectiveness Regulations and Pharmaceutical Innovation
by John Vernon & Joseph Golec & J. Stevens - 915-922 Comparative Effectiveness Research
by Marc Berger & David Grainger - 935-945 Comparative Effectiveness Without Head-to-Head Trials
by James Signorovitch & Eric Wu & Andrew Yu & Charles Gerrits & Evan Kantor & Yanjun Bao & Shiraz Gupta & Parvez Mulani - 957-967 No Head-to-Head Trial? Simulate the Missing Arms
by J.Jaime Caro & K. Ishak
September 2010, Volume 28, Issue 9
- 711-722 Using Conjoint Analysis and Choice Experiments to Estimate QALY Values
by Terry Flynn - 751-764 Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder
by Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus - 765-780 An Economic Evaluation of Colesevelam when Added to Metformin-, Insulinor Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus
by W. Simons & Michael Hagan
August 2010, Volume 28, Issue 8
- 615-628 Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms
by Joseph Golec & John Vernon - 675-685 Economic Burden of Epilepsy among the Privately Insured in the US
by Jasmina Ivanova & Howard Birnbaum & Yohanne Kidolezi & Ying Qiu & David Mallett & Sue Caleo
July 2010, Volume 28, Issue 7
- 521-538 Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement
by Alok Kapoor & Warren Chuang & Nila Radhakrishnan & Kenneth Smith & Dan Berlowitz & Jodi Segal & Jeffrey Katz & Elena Losina - 539-553 The State of Health Economic Evaluation Research in Nigeria
by Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza - 585-595 Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy
by Edward Wilson & Erika Sims & Stanley Musgrave & Lee Shepstone & Annie Blyth & Jamie Murdoch & H. Mugford & Elizabeth Juniper & Jon Ayres & Stephanie Wolfe & Daryl Freeman & Richard Gilbert & Ian Harvey & Elizabeth Hillyer & David Price - 597-608 Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma
by Edward Wilson & David Price & Stanley Musgrave & Erika Sims & Lee Shepstone & Jamie Murdoch & H. Mugford & Annie Blyth & Elizabeth Juniper & Jon Ayres & Stephanie Wolfe & Daryl Freeman & Richard Gilbert & Elizabeth Hillyer & Ian Harvey
June 2010, Volume 28, Issue 6
- 463-475 Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?
by Lesley Chim & Patrick Kelly & Glenn Salkeld & Martin Stockler - 477-487 Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis
by Roisin Adams & Cathal Walsh & Douglas Veale & Barry Bresnihan & Oliver FitzGerald & Michael Barry - 489-505 Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations
by Stephanie Earnshaw & Cheryl McDade & Libby Black & Christopher Bell & Michael Kattan - 507-520 Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?
by Brigitte Essers & Debby Helvoort-Postulart & Martin Prins & Martino Neumann & Carmen Dirksen
May 2010, Volume 28, Issue 5
- 381-393 Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting
by Richard Dodel & Svenja Happe & Ines Peglau & Geert Mayer & Jürgen Wasem & Jens-Peter Reese & Guido Giani & Max Geraedts & Claudia Trenkwalder & Wolfgang Oertel & Karin Stiasny-Kolster - 395-409 Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US
by Crystal Pike & Howard Birnbaum & Matt Schiller & Hari Sharma & Russel Burge & Eric Edgell - 411-427 Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease
by Denis Getsios & Steve Blume & K. Ishak & Grant Maclaine - 429-438 Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs
by D. Ackerly & Seth Glickman & Kevin Schulman
March 2010, Volume 28, Issue 3
- 185-199 The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
by Ágnes Benedict & Lara Verdian & Grant Maclaine
January 2010, Volume 28, Issue 1
- 35-46 Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma
by Eric Deconinck & Houda Miadi-Fargier & Claude Pen & Pauline Brice - 47-60 Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
by Virginia Rosen & Douglas Taylor & Hemangi Parekh & Ankur Pandya & David Thompson & Andreas Kuznik & David Waters & Michael Drummond & Milton Weinstein - 61-74 A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
by Lisa Meckley & James Gudgeon & Jeffrey Anderson & Marc Williams & David Veenstra
December 2009, Volume 27, Issue 12
- 991-1004 Cost Effectiveness of Herpes Zoster Vaccine in Canada
by Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick - 1005-1016 Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
by Tracy Lieu & G. Ray & Ismael Ortega-Sanchez & Ken Kleinman & Donna Rusinak - 1017-1029 Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
by Aline Gauthier & Andrea Manca & Susan Anton
November 2009, Volume 27, Issue 11
- 903-917 Cost Effectiveness in Low- and Middle-Income Countries
by Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills - 919-929 Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region
by Federico Augustovski & Cynthia Iglesias & Andrea Manca & Michael Drummond & Adolfo Rubinstein & Sebastián Martií
October 2009, Volume 27, Issue 10
- 797-806 Economic Evaluation and Cost-Effectiveness Thresholds
by John Vernon & Robert Goldberg & Joseph Golec - 873-886 Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective
by Peng Liubao & Wan Xiaomin & Tan Chongqing & Jon Karnon & Chen Gannong & Li Jianhe & Cui Wei & Luo Xia & Cao Junhua
August 2009, Volume 27, Issue 8
- 635-643 Estimating Drug Costs in Economic Evaluations in Ireland and the UK
by Dyfrig Hughes & Lesley Tilson & Michael Drummond - 657-679 Economic Burden of Follicular Non-Hodgkin’s Lymphoma
by Talia Foster & Jeffrey Miller & Mark Boye & Mason Russell
July 2009, Volume 27, Issue 7
- 533-545 Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
by Natasha Stout & Amy Knudsen & Chung Kong & Pamela McMahon & G. Gazelle - 609-621 Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
by Andrew Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez Mulani
May 2009, Volume 27, Issue 5
- 355-363 The Future Costs, Risks and Rewards of Drug Development
by Joseph Cook & Graeme Hunter & John Vernon - 391-403 The Cost of Dementia in Europe
by Linus Jönsson & Anders Wimo - 405-419 Utility Assessment in Patients with Mental Disorders
by Hans-Helmut König & Oliver Günther & Matthias Angermeyer & Christiane Roick
April 2009, Volume 27, Issue 4
- 267-279 Economic and Human Costs of Restless Legs Syndrome
by Thomas Reinhold & Falk Müller-Riemenschneider & Stefan Willich & Bernd Brüggenjürgen - 281-297 Reviewing the Cost Effectiveness of Rotavirus Vaccination
by Joke Bilcke & Philippe Beutels - 313-327 Cost Effectiveness of Drug-Eluting Stents In Belgian Practice
by Mattias Neyt & Chris Laet & Annemieke Ridder & Hans Brabandt - 329-339 Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder
by Laura Pizzi & Amy Talati & Eric Gemmen & Naomi Dahl & Thomas Bunz & Peter Sand
March 2009, Volume 27, Issue 3
- 221-230 The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone
by Peter Lindgren & Martin Buxton & Thomas Kahan & Neil Poulter & Björn Dahlöf & Peter Sever & Hans Wedel & Bengt Jönsson - 231-245 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
by Lieven Annemans & Vanessa Rémy & James Oyee & Nathalie Largeron - 247-261 Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan
by Ataru Igarashi & Hiroki Takuma & Takashi Fukuda & Kiichiro Tsutani
February 2009, Volume 27, Issue 2
- 91-93 Controlling Cervical Cancer
by Maurizio Bonati & Silvio Garattini - 95-112 Neuropathic Pain
by Alec O’Connor - 127-147 Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
by Fawziah Marra & Karine Cloutier & Bridgette Oteng & Carlo Marra & Gina Ogilvie - 159-165 Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV
by Kit Simpson & Alvin Strassburger & Walter Jones & Birgitta Dietz & Rukmini Rajagopalan
January 2009, Volume 27, Issue 1
- 25-37 Statin Therapy in Rheumatoid Arthritis
by Nick Bansback & Roberta Ara & Sue Ward & Aslam Anis & Hyon Choi - 55-68 Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma
by Philippe Fagnoni & Noel Milpied & Samuel Limat & Eric Deconinck & Virginie Nerich & Charles Foussard & Philippe Colombat & Jean-Luc Harousseau & Marie-Christine Woronoff-Lemsi - 81-90 Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
by Ulf-G Gerdtham & Philip Clarke & Alison Hayes & Soffia Gudbjornsdottir
December 2008, Volume 26, Issue 12
- 1005-1017 Measuring US Pharmaceutical Industry R&D Spending
by Joseph Golec & John Vernon - 1019-1035 Management and Prevention of Diabetic Foot Ulcers and Infections
by Ivy Chow & Elkin Lemos & Thomas Einarson - 1045-1064 A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
by Alec O’Connor & Katia Noyes & Robert Holloway
November 2008, Volume 26, Issue 11
- 911-924 The Impact of Influenza on Working Days Lost
by Martin Keech & Paul Beardsworth - 925-935 A Review of Health-Utility Data for Osteoarthritis
by Hirsch Ruchlin & Ralph Insinga - 937-949 A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
by D. Spackman & David Veenstra - 951-967 Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
by Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler - 969-981 Escitalopram and Duloxetine in Major Depressive Disorder
by Alan Wade & José-Luis Fernández & Clément François & Karina Hansen & Natalya Danchenko & Nicolas Despiege
August 2008, Volume 26, Issue 8
- 649-659 Assessing the Impact of Global Price Interdependencies
by Anke Richter